Literature DB >> 15119693

Effects of conventional and aggressive statin treatment on markers of endothelial function and inflammation.

Aina Hognestad1, Pål Aukrust, Ragnhild Wergeland, Oddvar Stokke, Lars Gullestad, Anne Grete Semb, Torbjørn Holm, Arne K Andreassen, John K Kjekshus.   

Abstract

BACKGROUND: Atherosclerosis is considered to be a chronic inflammatory disorder. Several large-scale clinical studies demonstrate that markers of inflammation, such as high-sensitivity C-reactive protein (hsCRP), fibrinogen, and soluble CD40 ligand, are potent and independent predictors of vascular risk. HYPOTHESIS: The study was undertaken to investigate the effect of increasing the statin dose from conventional to aggressive treatment on lipids levels, inflammation, and endothelial function in patients with coronary artery disease (CAD).
METHODS: We randomized 97 patients to either 20 mg simvastatin or 80 mg atorvastatin. Plasma levels of lipids, hsCRP, fibrinogen, soluble adhesion molecules, and nitric oxide-total were analyzed at baseline and after 6 months of treatment.
RESULTS: Lipid values were significantly reduced in both treatment groups, but with significantly greater reduction in the aggressively treated group. Furthermore, aggressive statin treatment significantly decreased hsCRP and fibrinogen, while only small reductions were seen in the conventionally treated group, resulting in significant differences between the two treatment groups (p < 0.001). Nitric oxide-total increased significantly in both treatment groups, although the increase was more pronounced in the aggressively treated group (22.6 vs. 15.6%).
CONCLUSION: Aggressive statin treatment significantly improved lipid status and reduced markers of inflammation and improved endothelial function compared with conventional treatment in patients with CAD. No interaction was observed, and high-dose treatment did not offer additional benefit compared with standard-dose treatment with respect to soluble adhesion molecules.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15119693      PMCID: PMC6654552          DOI: 10.1002/clc.4960270405

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  8 in total

1.  Antioxidant effects of simvastatin in primary and secondary prevention of coronary heart disease.

Authors:  A Tavridou; A Efthimiadis; I Efthimiadis; H Paschalidou
Journal:  Eur J Clin Pharmacol       Date:  2006-04-21       Impact factor: 2.953

2.  Simvastatin-induced changes in circulating oxidized low-density lipoprotein in different types of dyslipidemia.

Authors:  Anna Tavridou; Apostolos Efthimiadis; Ioannis Efthimiadis; Vangelis G Manolopoulos
Journal:  Heart Vessels       Date:  2010-07-31       Impact factor: 2.037

3.  Association of statin use with cognitive decline in elderly African Americans.

Authors:  S J Szwast; H C Hendrie; K A Lane; S Gao; S E Taylor; F Unverzagt; J Murrell; M Deeg; A Ogunniyi; M R Farlow; K S Hall
Journal:  Neurology       Date:  2007-11-06       Impact factor: 9.910

4.  Impact of chronic anticholesterol therapy on development of microvascular rarefaction in the metabolic syndrome.

Authors:  Adam G Goodwill; Stephanie J Frisbee; Phoebe A Stapleton; Milinda E James; Jefferson C Frisbee
Journal:  Microcirculation       Date:  2009-11       Impact factor: 2.628

5.  Reduction in blood pressure with statins: results from the UCSD Statin Study, a randomized trial.

Authors:  Beatrice A Golomb; Joel E Dimsdale; Halbert L White; Janis B Ritchie; Michael H Criqui
Journal:  Arch Intern Med       Date:  2008-04-14

Review 6.  Statins and blood pressure: is there an effect or not?

Authors:  Pantelis A Sarafidis; Angeliki I Kanaki; Anastasios N Lasaridis
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-06       Impact factor: 3.738

7.  The effect of aggressive versus conventional lipid-lowering therapy on markers of inflammatory and oxidative stress.

Authors:  Douwe J Mulder; Paul L van Haelst; Martgriet H Wobbes; Rijk O Gans; Felix Zijlstra; Johan F May; Andries J Smit; Jan Willem Cohen Tervaert; Jasper J van Doormaal
Journal:  Cardiovasc Drugs Ther       Date:  2007-03-07       Impact factor: 3.727

8.  Moderate-dose atorvastatin improves arterial endothelial function in patients with angina pectoris and normal coronary angiogram: a pilot study.

Authors:  Amela Kabaklić; Zlatko Fras
Journal:  Arch Med Sci       Date:  2017-06-12       Impact factor: 3.318

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.